- Trial phase
- Approved (marketed)
- Time to market
- Already on the market, FDA-approved since September 2015 (per local catalyst record). No unapproved Vraylar submission or PDUFA date is verifiable this session.
- Why 3/10
- No hard, dated binary for Vraylar is verifiable within the next ~12 months: the oral product has been FDA-approved since 2015-09-17 and no Vraylar PDUFA or pivotal readout appears in SecBot's ingested FDA/pipeline data, an approved product with no pending regulatory decision scores 3-5, and at 3 here because it is one product inside a ~$440B mega-cap whose stock historically moves little around FDA events.
Vraylar is an established, marketed revenue contributor inside AbbVie, not a standalone binary catalyst, don't buy the stock expecting a Vraylar-specific event.
Price Chart
Executive Summary
Vraylar (cariprazine) is an atypical antipsychotic marketed by AbbVie (ABBV, confirmed developer/ticker) and FDA-approved since 2015-09-17 per SecBot's catalyst record, an established product with no pending regulatory binary in the ingested data. The stock-level backdrop is constructive (analyst consensus 22 buy / 9 strong buy / 8 hold / 0 sell; mean price target $270.39 vs. $250.94 last price, ~11.6% implied upside; 12-month return +36.7%).
How It Works
An atypical (second-generation) antipsychotic. Unlike older drugs that fully block dopamine receptors, cariprazine is a "partial agonist", it partially stimulates dopamine D2/D3 and serotonin 5-HT1A receptors, steadying overactive brain signaling linked to schizophrenia and bipolar symptoms while aiming to avoid some of the movement and metabolic side effects of full blockers. This is standard public description of the drug; it could not be re-verified against the FDA label this session due to the web-search outage.
Trial Status
SecBot's local FDA/pipeline data records Vraylar's FDA approval catalyst dated 2015-09-17 (ticker ABBV). No Vraylar-specific FDA actions, new catalyst rows, or Phase 2/3 trial records appear in the last year of ingested data, consistent with a mature marketed drug rather than one in active pivotal development. The long-acting injectable (cariprazine LAI) program could not be confirmed this session because external web verification was unavailable.
The Two-Sided Case
Upcoming Catalysts
- AbbVie quarterly earnings (Q3 2026, roughly late October), Vraylar sales disclosed within the neuroscience segment; the Q2 2026 report (8-K filed 2026-07-31) is the most recent.
- Any company announcement on the cariprazine long-acting injectable (LAI) development program or regulatory submission, unverifiable this session, watch AbbVie news.
- Patent/generic litigation developments, flagged as an open risk that could not be confirmed via web this session.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
AbbVie Inc. 8-K ABBV ·Originating report